BioAxone Therapeutic
BioAxone Therapeutic is neuroscience company focused on the development and commercialization of technologies that target Rho signaling
About BioAxone Therapeutic
BioAxone Therapeutic is a clinical-stage biopharmaceutical company focused on developing treatments for neurotrauma and neurovascular disorders. Founded in 2000 by Dr. Lisa McKerracher, the company originated as a spin-out from a Canadian university. Dr. McKerracher, a serial entrepreneur and a recognized leader in translational neuroscience, transitioned from a 15-year academic career at McGill University and Université de Montréal to lead the company, leveraging her deep expertise in axon regeneration and Rho/ROCK signaling. Her work in the field has been recognized with multiple awards, including the Christopher Reeve Research Medal for Spinal Cord Repair.
The company's business model centers on the discovery, development, and subsequent out-licensing of its drug candidates to larger pharmaceutical partners for late-stage clinical trials and commercialization. This strategy is exemplified by the licensing of its ROCK2 inhibitor portfolio, including the lead compound NRL-1049 (formerly BA-1049), to Neurelis for the treatment of cerebral cavernous malformations (CCM). BioAxone has secured funding through various means, including venture capital, with investors like Desjardins Group and Fonds de solidarité FTQ, and has also been successful in obtaining over $6 million in non-dilutive SBIR grant funding from the NIH.
BioAxone's pipeline is built on a profound understanding of neuronal signaling pathways. A key focus is inhibiting the Rho pathway, which becomes hyperactivated after central nervous system trauma, preventing axon regeneration. Its lead candidate, BA-210 (Cethrin), is a Phase 3-ready, topically applied biologic Rho inhibitor designed to promote axon regeneration after acute spinal cord injury. BA-210 has received both Orphan Drug and Fast Track designations from the FDA. Another program targets cerebral cavernous malformation, a genetic disease causing leaky blood vessel clusters in the brain, with the orally available ROCK2 inhibitor NRL-1049. This drug aims to restore the integrity of the blood-brain barrier. Additionally, the company is developing BA-434, a preclinical self-delivering RNAi compound that targets PTEN, another protein that inhibits axon regeneration in adult neurons.
Source: Dealroom company dataNews
Open roles
BioAxone Therapeutic in the Montreal ecosystem
The BioAxone Therapeutic office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about BioAxone Therapeutic on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See BioAxone Therapeutic on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


